HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $6 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $6 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $6 price target.